Shares of Veru Inc. surged 15% to $2.68 Monday morning after the company posted fiscal third-quarter results that narrowed losses faster than Wall Street expected and confirmed its obesity drug study is ahead of schedule. The question now is whether this micro-cap company has enough cash and time to reach the data readouts that could make or break its future.
• The Loss Was Smaller Than Feared, but Spending Is Climbing. Veru reported a net loss of $7 million, or $0.30 per share, for the quarter ended June 30, compared with a loss of $7.3 million, or $0.50 per share, a year earlier. That beat the consensus estimate of a $0.32 loss. But research and development spending jumped to $4.4 million from $3 million a year ago, while administrative costs fell to $3.4 million from $5 million. In other words, Veru is funneling money away from overhead and into its drug trials — a deliberate trade-off, but one that keeps the company firmly unprofitable.
• The Obesity Trial Recruited More Patients Than Planned. The Phase 2b obesity trial of enobosarm combined with Novo Nordisk's semaglutide is fully enrolled with 239 patients, exceeding its 200-patient target. Bigger enrollment strengthens the statistical power of results. Interim body-composition data is expected in Q1 2027, with final results in Q4 2027.
The entire investment thesis hinges on that interim lean-mass data: if it replicates earlier positive signals, it validates the path to a larger Phase 3 trial; if it falls short, the longer-term case becomes far harder to make.
• Cash Looks Better, but the Runway Is Tight. Veru's cash balance rose to $23.9 million as of June 30 from $15.8 million a year earlier, though it burned $20.6 million in operations over the first nine months of fiscal 2026.
An active shelf registration allows Veru to raise up to $200 million by selling new shares over time — a lifeline, but one that dilutes existing shareholders. Analysts have flagged less than one year of cash runway, and shares outstanding already grew 62% in the prior year.
• A Patent Win and a Novo Nordisk Deal Add Credibility — With Caveats. Veru received a U.S. Patent Office notice of allowance covering its drug in combination with weight-loss medications, providing protection until at least October 2044.
The company also secured a clinical supply agreement with Novo Nordisk for semaglutide — a logistics deal, not a partnership, but a signal that the obesity giant is at least cooperating with Veru's research.
At roughly $36 million in market value, Veru is priced as a long-shot bet. Investors buying today are wagering that a single interim data readout five months away can reshape the company's trajectory — before the cash runs out.